-
公开(公告)号：US09861667B2
公开(公告)日：2018-01-09
申请号：US14777758
申请日：2014-05-18
CPC分类号： A61K35/76 , C12N7/00 , C12N2795/00033 , C12N2795/10121 , C12N2795/10132 , C12N2795/10321 , C12N2795/10332 , C12Q1/701 , Y02A50/481
摘要： In a first aspect, the present invention relates to new compositions comprising new bacteriophages allowing the prophylactic or therapeutic treatment of Salmonella infections in mammals and birds. Moreover, the present invention relates to the method for fighting Salmonella comprising the step of treating matter suspected to be afflicted with Salmonella with the bacteriophages according to the present invention. Moreover, the present invention relates to a method of treating or preventing Salmonella infection, in particular, in livestock.
-
公开(公告)号：US09617314B2
公开(公告)日：2017-04-11
申请号：US14112870
申请日：2012-04-20
申请人： Jin Town Wang , Tzu Lung Lin
发明人： Jin Town Wang , Tzu Lung Lin
IPC分类号： C07K14/005 , C12N7/00 , C07H21/04
CPC分类号： C12N7/00 , C07H21/04 , C07K14/005 , C12N2795/00021 , C12N2795/00022 , C12N2795/00032 , C12N2795/00033 , C12N2795/10221 , C12N2795/10222 , C12N2795/10232 , C12N2795/10233 , C12N2795/10322
摘要： The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.
-
公开(公告)号：US09605250B2
公开(公告)日：2017-03-28
申请号：US14111531
申请日：2012-04-12
IPC分类号： A61K38/43 , C12N9/24 , C12N9/36 , C12N1/06 , C12N15/62 , C07K14/47 , C12N9/48 , C07K14/005 , A61K38/00
CPC分类号： C12N9/2462 , A61K38/00 , C07K14/005 , C07K14/47 , C07K14/4742 , C07K2319/03 , C12N1/06 , C12N9/24 , C12N9/48 , C12N15/62 , C12N2795/00022 , C12N2795/00033 , C12N2795/10122 , C12N2795/10133 , C12N2795/10322 , C12N2795/10333 , C12Y302/01017 , Y02A50/475 , Y02A50/483
摘要： Provided herein are antibacterial compositions and methods of making and using the compositions.
-
公开(公告)号：US20160296571A1
公开(公告)日：2016-10-13
申请号：US14777758
申请日：2014-05-18
CPC分类号： A61K35/76 , C12N7/00 , C12N2795/00033 , C12N2795/10121 , C12N2795/10132 , C12N2795/10321 , C12N2795/10332 , C12Q1/701 , Y02A50/481
摘要： In a first aspect, the present invention relates to new compositions comprising new bacteriophages allowing the prophylactic or therapeutic treatment of Salmonella infections in mammals and birds. Moreover, the present invention relates to the method for fighting Salmonella comprising the step of treating matter suspected to be afflicted with Salmonella with the bacteriophages according to the present invention. Moreover, the present invention relates to a method of treating or preventing Salmonella infection, in particular, in livestock.
摘要翻译： 在第一方面，本发明涉及包含新的噬菌体的新组合物，其允许在哺乳动物和鸟类中预防或治疗沙门氏菌感染。 此外，本发明涉及沙门氏沙门氏菌的防治方法，其特征在于，包括利用本发明的噬菌体处理怀疑患有沙门氏菌的物质的步骤。 此外，本发明涉及特别是在家畜中治疗或预防沙门氏菌感染的方法。
-
5.发明授权公开(公告)号：US12012617B2
公开(公告)日：2024-06-18
申请号：US17534372
申请日：2021-11-23
发明人： Forest Rohwer , Jeremy J. Barr
IPC分类号： C12N7/00 , A61K35/76 , A61P1/04 , A61P31/04 , C07K14/005
CPC分类号： C12N7/00 , A61K35/76 , A61P31/04 , C07K14/005 , C07K2319/035 , C12N2795/00021 , C12N2795/00022 , C12N2795/00031 , C12N2795/00033 , Y02A50/30
摘要： Provided are compositions and methods for treating, ameliorating and preventing infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor. Provided are compositions and methods used to treat, prevent or ameliorate an infection, for example, an infection in the gastrointestinal tract, or bowel. Provided are compositions and methods for treating, ameliorating and/or preventing a condition comprising an abnormal, disrupted or pathological mucosal surface or mucus-covered epithelium, or a condition caused, modified or effected by an abnormal, disrupted or pathological microbiotia, wherein optionally the infection or condition comprises a diarrhea, a colitis, obesity, diabetes, autism, a cystic fibrosis, a dysentery, a gastrointestinal infection, a gastrointestinal inflammation, a gastrointestinal dysbiosis, a gastrointestinal upset, a lung infection, a bacterial infection, a viral infection, a secondary infection, an inflammation, a mucus hypersecretion, or a dysbiosis.
-
6.发明申请公开(公告)号：US20170218344A1
公开(公告)日：2017-08-03
申请号：US15437820
申请日：2017-02-21
发明人： Jin Town Wang , Tzu Lung Lin
IPC分类号： C12N7/00 , C07K14/005
CPC分类号： C12N7/00 , C07H21/04 , C07K14/005 , C12N2795/00021 , C12N2795/00022 , C12N2795/00032 , C12N2795/00033 , C12N2795/10221 , C12N2795/10222 , C12N2795/10232 , C12N2795/10233 , C12N2795/10322
摘要： The present invention relates to novel bacteriophages specific to Klebsiella pneumoniae strains, and compositions comprising the same. Particularly, polypeptides and their coding nucleic acid molecule of the novel bacteriophages are provided. The invention also relates to applications of the novel bacteriophages and the polypeptides in the detection/treatment/prevention of infection caused by Klebsiella pneumoniae strains. Development of immunogen and vaccine on the basis of the polypeptides are also provided.
-
公开(公告)号：US20140050713A1
公开(公告)日：2014-02-20
申请号：US14111531
申请日：2012-04-12
CPC分类号： C12N9/2462 , A61K38/00 , C07K14/005 , C07K14/47 , C07K14/4742 , C07K2319/03 , C12N1/06 , C12N9/24 , C12N9/48 , C12N15/62 , C12N2795/00022 , C12N2795/00033 , C12N2795/10122 , C12N2795/10133 , C12N2795/10322 , C12N2795/10333 , C12Y302/01017 , Y02A50/475 , Y02A50/483
摘要： Provided herein are antibacterial compositions and methods of making and using the compositions.
摘要翻译： 本文提供了抗菌组合物和制备和使用组合物的方法。
-
公开(公告)号：US20130121967A1
公开(公告)日：2013-05-16
申请号：US13702599
申请日：2011-06-08
申请人： Robert Leah
发明人： Robert Leah
IPC分类号： A61K35/76
CPC分类号： C12N7/00 , A61K35/76 , C12N2795/00021 , C12N2795/00032 , C12N2795/00033 , C12N2795/00051 , C12N2795/10121 , C12N2795/10322 , C12Q1/04 , Y02A50/475 , Y02A50/481
摘要： The present invention relates to a composition comprising obligate lytic bacteriophages generated by a method comprising subjecting normally in vivo lysogenic, pseudolysogenic or temperate bacteriophages to genetic modifications in vitro, which alters the biological activity of one or more of the individual gene products for establishing, maintaining, controlling or regulating the lysogenic life cycle of the bacteriophages, thereby converting them to obligate lytic bacteriophages, wherein the genetic modification includes modification of a single gene in the operon containing a gene resulting in a gene product for establishing, maintaining, controlling or regulating the lysogenic life cycle of the bacteriophages.
-
公开(公告)号：US20240352428A1
公开(公告)日：2024-10-24
申请号：US18294138
申请日：2022-08-02
CPC分类号： C12N7/00 , C12N9/22 , C12N9/88 , C12N15/11 , C12N15/90 , C12Y402/02003 , C12Y402/02011 , C12N2310/20 , C12N2795/00022 , C12N2795/00033
摘要： Provided herein are bacteriophages engineered to express an exopolysaccharide (EPS) depolymerase for treating bacterial infections. In some embodiments, the EPS depolymerase comprises alginate lyase. Also envisioned within the scope of the invention are compositions comprising one or more of the bacteriophages, methods for treating bacterial infections, and kits comprising the compositions described herein.
-
10.发明公开公开(公告)号：US20240279619A1
公开(公告)日：2024-08-22
申请号：US18642329
申请日：2024-04-22
申请人： San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation
发明人： Forest ROHWER , Jeremy J. BARR
IPC分类号： C12N7/00 , A61K35/76 , A61P31/04 , C07K14/005
CPC分类号： C12N7/00 , A61K35/76 , A61P31/04 , C07K14/005 , C07K2319/035 , C12N2795/00021 , C12N2795/00022 , C12N2795/00031 , C12N2795/00033 , Y02A50/30
摘要： Provided are compositions and methods for treating, ameliorating and preventing infections, disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where a microbial or bacterial flora is at least one causative or symptom-producing factor. Provided are compositions and methods used to treat, prevent or ameliorate an infection, for example, an infection in the gastrointestinal tract, or bowel. Provided are compositions and methods for treating, ameliorating and/or preventing a condition comprising an abnormal, disrupted or pathological mucosal surface or mucus-covered epithelium, or a condition caused, modified or effected by an abnormal, disrupted or pathological microbiotia, wherein optionally the infection or condition comprises a diarrhea, a colitis, obesity, diabetes, autism, a cystic fibrosis, a dysentery, a gastrointestinal infection, a gastrointestinal inflammation, a gastrointestinal dysbiosis, a gastrointestinal upset, a lung infection, a bacterial infection, a viral infection, a secondary infection, an inflammation, a mucus hypersecretion, or a dysbiosis.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.014 秒)
